Mason Henderson Dies at 21 After 6-Week Fight for $8,700-a-Month Lynparza

1 articles · Updated · CBS New York · Sep 21

Henderson, a Texas patient with an ultra-rare brain cancer that spread to his spinal fluid, died May 4 after taking Lynparza for nearly two months; the drug reached him only after a six-week coverage battle.
Liviniti denied the Jan. 16 prescription on Jan. 30 because Lynparza was not approved for his diagnosis, and Jefferson County upheld the refusal despite specialists arguing the Merck-AstraZeneca drug was biologically justified.
AstraZeneca initially rejected a donation request, then shipped 60 pills a day after Henderson's mother publicly appealed on social media in March; out-of-pocket treatment would have cost about $8,700 a month.
Doctors said faster access might have helped but could not say whether it would have extended his life, underscoring how rare-cancer patients can be blocked when genomic evidence outpaces FDA labels and insurer guidelines.
Rare cancers account for about a quarter of U.S. cases, yet many lack standard treatments or trial access, leaving reimbursement decisions poorly aligned with precision-medicine approaches.